Increasing Response Rates in Immuno-Oncology with Artificial Intelligence

There are multiple factors contributing to the immune system recognizing cancer and properly launching adaptive immune reaction against it. Ardigen research combines the expertise in Artificial Intelligence, Bioinformatics, Cancer Biology, Immunology and Microbiome to deliver technologies that lead to significantly increased response rates to immunotherapies.


Decoding microbiome for clinical success

Ardigen improves therapeutic outcome by translating microbiome with AI-reinforced biology

Ardigen aids drug development with digital microbiome solutions. By discovering actionable signatures in the
metagenomic haystack, we help you to enter subsequent stages on your way towards an effective pharmaceutical.
At Ardigen, we screen for the most meaningful insights to explain the biology behind the therapeutic potential of
the microbiome. By exploring all the metagenomic information, we reveal previously undiscovered traits.

Decoding microbiome schema

Our approach for translational microbiomics

Ardigen addresses the challenges of drug development, starting with patients’ microbial and clinical data. We
provide insight into the therapy-modulating interplay between host and microbiome, by exploring the functional
potential of commensal microbiota. In the process of revealing microbial signatures, we decode biological
findings to achieve clinical benefits.

Our approach for translational microbiomics schema

Our dataset

Our research is supported by a broad network of clinical and academic collaborators, orchestrated by Ardigen’s Clinical Operations unit.

Our dataset schema

Immunity by design with Artificial Intelligence

Effective shared and personalized cancer vaccine design proved to be challenging. The therapies in multiple

clinical trials failed to stimulate immune responses strong enough to light the disease, and in a few cases caused

severe toxicity towards self-antigens. To solve these challenges, Ardigen developed ArdImmune Vax – an Artificial

Intelligence-driven vaccine design platform. The speed of ArdImmune Vax enables clinically relevant windows to

be reached even with most demanding therapies. ArdImmune Vax can be used beyond cancer and move viral

vaccine design into the era of AI.


Immunity by design schema

Neoantigen cancer vaccinesDesigning immune response with AI

ArdImmune Vax uses next generation sequencing of cancer tissue and healthy samples to extract information about candidate therapeutic neoepitopes. These neoepitopes are evaluated for their properties including the potential to induce specific and effective T cell responses, safety and manufacturability. The success of the cancer treatment also depends on efficiently covering the clonal structure of the tumor, which we consider in ArdImmune Vax.

Quickly prepared prioritized list of neoepitopes enables therapy development optimized for effectiveness, cost and speed of delivery. 

Neoantigen cancer vaccines schema

Adoptive Cell Therapy Weaponizing T cells and DCs with AI

Preparing thousands of cells bearing the same TCR, which are to be infused into patient, you need to be sure it will find its target. You are also on the clock when screening for the right TCR. Therefore, accurate prioritization of peptide-HLA pairs is crucial for you to meet your timeline with an effective therapy.

The same is valid for the selection of epitopes to be loaded into dendritic cells that afterwards are used as a delivery system.

Ardigen in silico platform will help you reach these goals.

Adoptive Cell Therapy  schema
WEBINAR: Squeeze the data: the modern way of decoding the microbiome
WEBINAR: Gains of microbiome studies - decoding metagenomic data
VIDEO: Why is the gut microbiome important and crucial for our health?
INTERVIEW: Ardigen Microbiome Translational Platform
PRESENTATION: Ardigen presentation Bio Convenction 2020
WEBINAR: Using AI to design vaccine protecting from COVID-19
WEBINAR: Immune escape mechanisms in neoantigen-driven therapies
WEBINAR: How AI can help design cancer vaccines and adoptive cell therapies?